Grace Science says FDA bottleneck jeopardizes rare disease therapy

June 9, 2026 02:22 PM EDT Cell/Gene TxFDA+ A fa­ther built a gene ther­a­py for his daugh­ter. He says an FDA re­quest is the bot­tle­neck Zachary Brennan Senior Editor Grace Sci­ence ap­peared to be one of the few com­pa­nies fight­ing ul­tra-rare dis­eases whose gene ther­a­py can­di­date might make it across the fin­ish line. Co-found­ed … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER